Cai Jing Wang·2025-09-10 15:51Core Viewpoint - Taiji Group's subsidiary has received clinical trial approval for Semaglutide injection, a GLP-1 receptor agonist for type 2 diabetes management and weight control [1][2]. Group 1: Company Developments - Taiji Group's subsidiary, Chongqing Fuling Pharmaceutical Factory, has obtained the clinical trial approval notice from the National Medical Products Administration for Semaglutide injection [1]. - The approved indication for the clinical trial is for blood sugar control in adult patients with type 2 diabetes who have inadequate control despite treatment with metformin and/or sulfonylureas [1]. - The company has invested approximately RMB 44.1834 million in the research and development of this project [2]. Group 2: Industry Context - Semaglutide is a long-acting GLP-1 receptor agonist that stimulates insulin production, suppresses glucagon secretion, and reduces appetite, playing a significant role in treating type 2 diabetes and aiding weight management [1]. - The original product of Semaglutide injection was developed by Novo Nordisk, which reported total revenue of USD 29.296 billion for the product in 2024 [2]. - Currently, Novo Nordisk is the only company with the Semaglutide injection product approved for market in China [1].